Clinical Trial of RedHill’s Potential Crohn’s Disease Therapy Set to Continue as Planned

Clinical Trial of RedHill’s Potential Crohn’s Disease Therapy Set to Continue as Planned
RedHill Biopharma Ltd. An Israeli biopharmaceutical company announced that an independent Data and Safety Monitoring Board (DSMB) recommended their MAP US study to continue as planned without any modifications.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *